In June 2023, the Company approved a reduction in force intended to restructure and strategically align its workforce with the Company’s strategy and to reduce the Company’s operating costs, primarily in the Consumer and Research Services segment. Subsequently in August 2023, the Company approved another reduction in force primarily intended to restructure and strategically align the Therapeutics workforce. As a result, during the fiscal year ended March 31, 2024, the Company recorded restructuring charges of $8.4 million, within restructuring and other charges in the

consolidated statements of operations, of which $6.7 million, was related to cash severance payments and benefits continuation.


	One-Time Employee Termination Benefits
	(in thousands)
Accrued restructuring costs included in accrued expenses and other current liabilities as of March 31, 2023	$	—
Restructuring charges incurred during the period	8,368
Amounts paid during the period	(8,346)
Accrued restructuring costs included in accrued expenses and other current liabilities as of March 31, 2024	$	22

The Company does not expect to incur any further material expenses in connection with the reduction in force events that occurred in June and August 2023.